Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001072613-24-000602
Filing Date
2024-08-05
Accepted
2024-08-05 21:00:10
Documents
1
Group Members
ANTHONY A. FLORENCE, JR.FOREST BASKETTMOHAMAD H. MAKHZOUMINEA 15 GP, LLCNEA PARTNERS 15, L.P.NEW ENTERPRISE ASSOCIATES 15, L.P.SCOTT D. SANDELL

Document Format Files

Seq Description Document Type Size
1 GROWTH EQUITY OPPORTUNITIES FUND IV (ADDEX THERAPEUTICS) - SCHEDULE 13D/A(#6) geoiv-addex_18859.htm SC 13D/A 354553
  Complete submission text file 0001072613-24-000602.txt   356505
Mailing Address CHEMIN DES MINES 9 GENEVA V8 CH-1202
Business Address CHEMIN DES MINES 9 GENEVA V8 CH-1202 01141228841555
Addex Therapeutics Ltd. (Subject) CIK: 0001574232 (see all company filings)

EIN.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-91805 | Film No.: 241176765
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 1954 GREENSPRING DRIVE SUITE 600 TIMONIUM MD 21093
Business Address 1954 GREENSPRING DRIVE SUITE 600 TIMONIUM MD 21093 410-842-4000
Growth Equity Opportunities Fund IV, LLC (Filed by) CIK: 0001644965 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A